Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 11 | 2023 | 144 | 5.770 |
Why?
|
| Bone Neoplasms | 9 | 2023 | 120 | 4.590 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2022 | 54 | 2.020 |
Why?
|
| Retrospective Studies | 16 | 2023 | 3612 | 1.320 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 206 | 1.140 |
Why?
|
| Margins of Excision | 2 | 2022 | 31 | 0.900 |
Why?
|
| Giant Cell Tumor of Bone | 2 | 2022 | 15 | 0.890 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 90 | 0.880 |
Why?
|
| Chondrosarcoma | 1 | 2023 | 33 | 0.850 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 38 | 0.850 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 60 | 0.830 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 79 | 0.820 |
Why?
|
| Neutrophils | 1 | 2023 | 110 | 0.800 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.780 |
Why?
|
| Prognosis | 7 | 2023 | 825 | 0.730 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 9 | 0.730 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.720 |
Why?
|
| Osteosarcoma | 1 | 2021 | 37 | 0.710 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.710 |
Why?
|
| Humans | 22 | 2023 | 28436 | 0.690 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 186 | 0.660 |
Why?
|
| Osteoarthritis | 1 | 2022 | 328 | 0.580 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2022 | 821 | 0.560 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2022 | 625 | 0.490 |
Why?
|
| Treatment Outcome | 6 | 2023 | 3615 | 0.460 |
Why?
|
| Child | 4 | 2021 | 1420 | 0.420 |
Why?
|
| Limb Salvage | 2 | 2023 | 12 | 0.420 |
Why?
|
| Survival Rate | 4 | 2021 | 356 | 0.410 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 66 | 0.390 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 37 | 0.380 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 34 | 0.380 |
Why?
|
| Adolescent | 4 | 2021 | 2307 | 0.380 |
Why?
|
| Young Adult | 4 | 2021 | 2069 | 0.370 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 371 | 0.350 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 352 | 0.330 |
Why?
|
| Adult | 6 | 2022 | 8107 | 0.330 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 1859 | 0.320 |
Why?
|
| Prospective Studies | 2 | 2023 | 1809 | 0.270 |
Why?
|
| Middle Aged | 6 | 2021 | 9269 | 0.260 |
Why?
|
| Curettage | 2 | 2022 | 9 | 0.230 |
Why?
|
| Biopsy | 2 | 2023 | 220 | 0.220 |
Why?
|
| Lower Extremity | 1 | 2023 | 39 | 0.220 |
Why?
|
| Surgical Flaps | 1 | 2023 | 51 | 0.220 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 16 | 0.210 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 16 | 0.210 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 59 | 0.210 |
Why?
|
| Bone Cements | 2 | 2022 | 90 | 0.210 |
Why?
|
| Lymphocytes | 1 | 2023 | 63 | 0.210 |
Why?
|
| Female | 6 | 2021 | 15730 | 0.210 |
Why?
|
| Preoperative Care | 1 | 2023 | 125 | 0.210 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4857 | 0.210 |
Why?
|
| Necrosis | 1 | 2022 | 26 | 0.200 |
Why?
|
| Male | 6 | 2021 | 15291 | 0.200 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.200 |
Why?
|
| Replantation | 1 | 2022 | 10 | 0.200 |
Why?
|
| Reoperation | 3 | 2022 | 917 | 0.200 |
Why?
|
| Femur | 2 | 2022 | 382 | 0.200 |
Why?
|
| Infant | 2 | 2021 | 587 | 0.200 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 9 | 0.190 |
Why?
|
| Child, Preschool | 2 | 2021 | 688 | 0.190 |
Why?
|
| Metastasectomy | 1 | 2021 | 7 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 553 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2021 | 654 | 0.190 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 35 | 0.190 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 53 | 0.190 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 89 | 0.190 |
Why?
|
| SEER Program | 1 | 2021 | 41 | 0.180 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 52 | 0.180 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 22 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 89 | 0.180 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 177 | 0.180 |
Why?
|
| Ganglion Cysts | 1 | 2020 | 6 | 0.170 |
Why?
|
| Contracture | 1 | 2020 | 14 | 0.170 |
Why?
|
| Aged | 4 | 2021 | 9277 | 0.170 |
Why?
|
| Allografts | 1 | 2021 | 218 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 383 | 0.160 |
Why?
|
| Elbow Joint | 1 | 2020 | 123 | 0.160 |
Why?
|
| Time Factors | 1 | 2022 | 1491 | 0.140 |
Why?
|
| Hip Prosthesis | 1 | 2022 | 552 | 0.130 |
Why?
|
| Spinal Fusion | 1 | 2020 | 465 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 30 | 0.090 |
Why?
|
| Tibia | 1 | 2010 | 244 | 0.080 |
Why?
|
| Cell Division | 1 | 2022 | 83 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 47 | 0.050 |
Why?
|
| Apoptosis | 1 | 2022 | 205 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2021 | 77 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 170 | 0.040 |
Why?
|
| Joint Capsule Release | 1 | 2020 | 10 | 0.040 |
Why?
|
| Elbow | 1 | 2020 | 49 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 307 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 353 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2022 | 498 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 536 | 0.040 |
Why?
|
| Risk Factors | 1 | 2022 | 2408 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 1926 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 2010 | 23 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 81 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 362 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 730 | 0.020 |
Why?
|